Results demonstrated the potential of using imaging biomarkers from PSMA-PET/CT images for prognosis prediction before the treatment, which provides clinicians valuable information for customizing the treatment paradigm to improve the outcomes for primary prostate cancer patients. This evidence concerns the gene FOLH1 and Familial prostate cancer.